دورية أكاديمية
أعرض في EDS

Insights into immune microenvironment and therapeutic targeting in androgen-associated prostate cancer subtypes.

التفاصيل البيبلوغرافية
العنوان: Insights into immune microenvironment and therapeutic targeting in androgen-associated prostate cancer subtypes.
المؤلفون: Huang L; Department of Urology, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, Hunan, China., Xie Y; Department of Urology, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, Hunan, China., Jiang S; Department of Urology, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, Hunan, China., Dai T; Department of Urology, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, Hunan, China., Xu Z; Department of Urology, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, Hunan, China., Shan H; Department of Emergency Medicine, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, China. shirleyv5@163.com.
المصدر: Scientific reports [Sci Rep] 2024 Aug 04; Vol. 14 (1), pp. 18036. Date of Electronic Publication: 2024 Aug 04.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Tumor Microenvironment*/immunology , Tumor Microenvironment*/genetics , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/immunology , Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/metabolism , Androgens*/metabolism , Gene Expression Regulation, Neoplastic*/drug effects, Humans ; Male ; Gene Expression Profiling ; Prognosis ; Transcriptome ; Computational Biology/methods
مستخلص: Prostate cancer, one of the most prevalent malignancies among men worldwide, is intricately linked with androgen signaling, a key driver of its pathogenesis and progression. Understanding the diverse expression patterns of androgen-responsive genes holds paramount importance in unraveling the biological intricacies of this disease and prognosticating patient outcomes. In this study, utilizing consensus clustering analysis based on the expression profiles of androgen-responsive genes, prostate cancer patients from the TCGA database were stratified into two distinct subtypes, denoted as C1 and C2. Notably, the C1 subtype demonstrates a significant upregulation of certain genes, such as CGA and HSD17B12, along with a shorter progression-free survival duration, indicating a potentially unfavorable prognosis. Further analyses elucidated the immune infiltration disparities, mutation landscapes, and gene functional pathways characteristic of each subtype. Through integrated bioinformatics approaches and machine learning techniques, key genes such as BIRC5, CENPA, and MMP11 were identified as potential therapeutic targets, providing novel insights into tailored treatment strategies. Additionally, single-cell transcriptome analysis shed light on the heterogeneous expression patterns of these genes across different cell types within the tumor microenvironment. Furthermore, virtual screening identified candidate drugs targeting the BIRC5 receptor, offering promising avenues for drug development. Collectively, these findings deepen our understanding of prostate cancer biology, paving the way for personalized therapeutic interventions and advancing the quest for more effective treatments in prostate cancer management.
(© 2024. The Author(s).)
References: Med Clin North Am. 2020 Nov;104(6):1051-1062. (PMID: 33099450)
Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2114324119. (PMID: 35584120)
Mod Pathol. 2018 Jan;31(S1):S110-121. (PMID: 29297495)
Eur Urol. 2002 Mar;41(3):335-41. (PMID: 12180238)
Cell. 2010 Jul 23;142(2):196-8. (PMID: 20655462)
Endocr Rev. 2021 May 25;42(3):354-373. (PMID: 33480983)
Adv Clin Chem. 2022;108:73-104. (PMID: 35659062)
Genes Dev. 2018 Sep 1;32(17-18):1105-1140. (PMID: 30181359)
Mol Oncol. 2022 Jul;16(13):2518-2536. (PMID: 34919781)
Cancer Res. 2020 Apr 15;80(8):1615-1623. (PMID: 32066566)
Nat Rev Urol. 2020 Jun;17(6):321-338. (PMID: 32358562)
Cancer Res. 2023 Oct 2;83(19):3192-3204. (PMID: 37527336)
Ann Oncol. 2020 Apr;31(4):470-479. (PMID: 32139297)
Int J Mol Sci. 2022 Nov 17;23(22):. (PMID: 36430730)
Eur Urol. 2022 May;81(5):446-455. (PMID: 35058087)
World J Oncol. 2019 Apr;10(2):63-89. (PMID: 31068988)
Cancer Lett. 2021 Oct 10;518:1-9. (PMID: 34118355)
Int J Oncol. 2023 Nov;63(5):. (PMID: 37732538)
Drug Resist Updat. 2023 May;68:100962. (PMID: 37068396)
J Clin Oncol. 2023 Sep 10;41(26):4267-4278. (PMID: 37429011)
Expert Opin Pharmacother. 2022 Jun;23(9):1015-1033. (PMID: 35108137)
Sci Adv. 2024 Mar;10(9):eadi2742. (PMID: 38416822)
Eur Urol. 2023 Mar;83(3):241-248. (PMID: 36609003)
Endocrinology. 2016 Oct;157(10):3719-3730. (PMID: 27490311)
J Exp Clin Cancer Res. 2022 Feb 2;41(1):46. (PMID: 35109899)
J Transl Med. 2021 Oct 9;19(1):417. (PMID: 34627268)
J Natl Compr Canc Netw. 2023 Oct;21(10):1067-1096. (PMID: 37856213)
BMC Cancer. 2022 Mar 25;22(1):322. (PMID: 35331169)
Int J Mol Sci. 2013 Jul 26;14(8):15615-35. (PMID: 23896594)
J Exp Clin Cancer Res. 2019 Aug 22;38(1):368. (PMID: 31439015)
Nat Commun. 2022 Jul 28;13(1):4364. (PMID: 35902588)
J Assist Reprod Genet. 2018 May;35(5):913-919. (PMID: 29476300)
Front Endocrinol (Lausanne). 2021 Mar 23;12:657360. (PMID: 33833737)
Int J Oncol. 2024 Feb;64(2):. (PMID: 38099379)
Cell Rep Med. 2023 Oct 17;4(10):101199. (PMID: 37738978)
Annu Rev Pharmacol Toxicol. 2022 Jan 6;62:131-153. (PMID: 34449248)
Eur Urol Focus. 2022 Jul;8(4):913-915. (PMID: 36055957)
Int J Biol Sci. 2023 Oct 16;19(16):5218-5232. (PMID: 37928273)
Cancer Treat Rev. 2019 Dec;81:101871. (PMID: 31698174)
Expert Rev Anticancer Ther. 2022 Feb;22(2):191-202. (PMID: 34928193)
معلومات مُعتمدة: 2022JJ40249 Natural Science Foundation of Hunan Province of China; 202204053845 Scientific Research Project of Hunan Provincial Health Commission
فهرسة مساهمة: Keywords: Androgen-responsive genes; Immune infiltration; Machine learning; Prostate cancer; Tumor microenvironment
المشرفين على المادة: 0 (Androgens)
تواريخ الأحداث: Date Created: 20240804 Date Completed: 20240804 Latest Revision: 20240809
رمز التحديث: 20240809
مُعرف محوري في PubMed: PMC11298543
DOI: 10.1038/s41598-024-68863-0
PMID: 39098988
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-68863-0